Department of Radiology, University College Hospital Galway, Galway University Hospitals, Newcastle Rd., Galway, Ireland.
AJR Am J Roentgenol. 2010 Jan;194(1):W91-W103. doi: 10.2214/AJR.09.2637.
The purpose of this review is to assist interpreting radiologists in becoming familiar with the role of PET/CT in baseline staging and therapeutic response assessment in the management of lymphoma, in becoming aware of imaging pitfalls, and in understanding the natural behavior of lymphoma and the therapeutic options.
Therapeutic strategies for the management of lymphoma are constantly being refined to improve long-term survival with the lowest risk of toxicity to the patient. PET/CT is accurate for baseline staging and yields important prognostic information for determining the most appropriate initial treatment. Used for evaluation of treatment response, PET/CT can depict residual viable malignant lesions with greater accuracy than can other imaging techniques. The findings thereby influence decisions about the need for additional or alternative treatment.
本综述旨在帮助解读放射科医生熟悉 PET/CT 在淋巴瘤管理中的基线分期和治疗反应评估中的作用，了解影像学陷阱，并理解淋巴瘤的自然病程和治疗选择。
淋巴瘤治疗策略不断得到完善，以提高长期生存率，并将对患者的毒性风险降至最低。PET/CT 对基线分期准确，并为确定最合适的初始治疗提供重要的预后信息。用于评估治疗反应时，与其他影像学技术相比，PET/CT 能更准确地描绘残留的有活性的恶性病变。这些发现影响了是否需要额外或替代治疗的决策。
